دورية أكاديمية
Immune Response to SARS-CoV-2 Third Vaccine in Patients With Rheumatoid Arthritis Who Had No Seroconversion After Primary 2-Dose Regimen With Inactivated or Vector-Based Vaccines.
| العنوان: | Immune Response to SARS-CoV-2 Third Vaccine in Patients With Rheumatoid Arthritis Who Had No Seroconversion After Primary 2-Dose Regimen With Inactivated or Vector-Based Vaccines. |
|---|---|
| المؤلفون: | Isnardi CA; C.A. Isnardi, MD, Research Unit - Argentine Society of Rheumatology, and Instituto de Rehabilitación Psicofísica, Rheumatology Section., Cerda OL; O.L. Cerda, MD, E.E. Schneeberger, MD, M.A. Alfaro, MD, B.M. Roldán, MD, A.B. Gómez Vara, MD, P. Giorgis, MD, R.A. Ezquer, MD, M.G. Crespo Rocha, MD, C.R. Reyes Gómez, MD, M.Á. Correa, MD, M.G. Rosemffet, MD, V.C. Abarza, MD, M. Perandones, MD, G. Citera, MD, Instituto de Rehabilitación Psicofísica, Rheumatology Section., Landi M; M. Landi, MD, C. Calle Montoro, MD, S. Catalan Pellet, MD, C. Reimundes, MD, P. Maid, MD, Austral University Hospital, Rheumatology Department., Cruces L; L. Cruces, BCh, Y. Longueira, MSc, G. Turk, PhD, M.F. Quiroga, PhD, N. Laufer, MD, PhD, Universidad de Buenos Aires, Consejo Nacional de Investigaciones Científicas y Técnicas, Instituto de Investigaciones Biomédicas en Retrovirus y Sida (INBIRS), Facultad de Medicina, Ciudad Autónoma de Buenos Aires., Schneeberger EE; O.L. Cerda, MD, E.E. Schneeberger, MD, M.A. Alfaro, MD, B.M. Roldán, MD, A.B. Gómez Vara, MD, P. Giorgis, MD, R.A. Ezquer, MD, M.G. Crespo Rocha, MD, C.R. Reyes Gómez, MD, M.Á. Correa, MD, M.G. Rosemffet, MD, V.C. Abarza, MD, M. Perandones, MD, G. Citera, MD, Instituto de Rehabilitación Psicofísica, Rheumatology Section., Montoro CC; M. Landi, MD, C. Calle Montoro, MD, S. Catalan Pellet, MD, C. Reimundes, MD, P. Maid, MD, Austral University Hospital, Rheumatology Department., Alfaro MA; O.L. Cerda, MD, E.E. Schneeberger, MD, M.A. Alfaro, MD, B.M. Roldán, MD, A.B. Gómez Vara, MD, P. Giorgis, MD, R.A. Ezquer, MD, M.G. Crespo Rocha, MD, C.R. Reyes Gómez, MD, M.Á. Correa, MD, M.G. Rosemffet, MD, V.C. Abarza, MD, M. Perandones, MD, G. Citera, MD, Instituto de Rehabilitación Psicofísica, Rheumatology Section., Roldán BM; O.L. Cerda, MD, E.E. Schneeberger, MD, M.A. Alfaro, MD, B.M. Roldán, MD, A.B. Gómez Vara, MD, P. Giorgis, MD, R.A. Ezquer, MD, M.G. Crespo Rocha, MD, C.R. Reyes Gómez, MD, M.Á. Correa, MD, M.G. Rosemffet, MD, V.C. Abarza, MD, M. Perandones, MD, G. Citera, MD, Instituto de Rehabilitación Psicofísica, Rheumatology Section., Gómez Vara AB; O.L. Cerda, MD, E.E. Schneeberger, MD, M.A. Alfaro, MD, B.M. Roldán, MD, A.B. Gómez Vara, MD, P. Giorgis, MD, R.A. Ezquer, MD, M.G. Crespo Rocha, MD, C.R. Reyes Gómez, MD, M.Á. Correa, MD, M.G. Rosemffet, MD, V.C. Abarza, MD, M. Perandones, MD, G. Citera, MD, Instituto de Rehabilitación Psicofísica, Rheumatology Section., Giorgis P; O.L. Cerda, MD, E.E. Schneeberger, MD, M.A. Alfaro, MD, B.M. Roldán, MD, A.B. Gómez Vara, MD, P. Giorgis, MD, R.A. Ezquer, MD, M.G. Crespo Rocha, MD, C.R. Reyes Gómez, MD, M.Á. Correa, MD, M.G. Rosemffet, MD, V.C. Abarza, MD, M. Perandones, MD, G. Citera, MD, Instituto de Rehabilitación Psicofísica, Rheumatology Section., Ezquer RA; O.L. Cerda, MD, E.E. Schneeberger, MD, M.A. Alfaro, MD, B.M. Roldán, MD, A.B. Gómez Vara, MD, P. Giorgis, MD, R.A. Ezquer, MD, M.G. Crespo Rocha, MD, C.R. Reyes Gómez, MD, M.Á. Correa, MD, M.G. Rosemffet, MD, V.C. Abarza, MD, M. Perandones, MD, G. Citera, MD, Instituto de Rehabilitación Psicofísica, Rheumatology Section., Crespo Rocha MG; O.L. Cerda, MD, E.E. Schneeberger, MD, M.A. Alfaro, MD, B.M. Roldán, MD, A.B. Gómez Vara, MD, P. Giorgis, MD, R.A. Ezquer, MD, M.G. Crespo Rocha, MD, C.R. Reyes Gómez, MD, M.Á. Correa, MD, M.G. Rosemffet, MD, V.C. Abarza, MD, M. Perandones, MD, G. Citera, MD, Instituto de Rehabilitación Psicofísica, Rheumatology Section., Reyes Gómez CR; O.L. Cerda, MD, E.E. Schneeberger, MD, M.A. Alfaro, MD, B.M. Roldán, MD, A.B. Gómez Vara, MD, P. Giorgis, MD, R.A. Ezquer, MD, M.G. Crespo Rocha, MD, C.R. Reyes Gómez, MD, M.Á. Correa, MD, M.G. Rosemffet, MD, V.C. Abarza, MD, M. Perandones, MD, G. Citera, MD, Instituto de Rehabilitación Psicofísica, Rheumatology Section., de Los Ángeles Correa M; O.L. Cerda, MD, E.E. Schneeberger, MD, M.A. Alfaro, MD, B.M. Roldán, MD, A.B. Gómez Vara, MD, P. Giorgis, MD, R.A. Ezquer, MD, M.G. Crespo Rocha, MD, C.R. Reyes Gómez, MD, M.Á. Correa, MD, M.G. Rosemffet, MD, V.C. Abarza, MD, M. Perandones, MD, G. Citera, MD, Instituto de Rehabilitación Psicofísica, Rheumatology Section., Rosemffet MG; O.L. Cerda, MD, E.E. Schneeberger, MD, M.A. Alfaro, MD, B.M. Roldán, MD, A.B. Gómez Vara, MD, P. Giorgis, MD, R.A. Ezquer, MD, M.G. Crespo Rocha, MD, C.R. Reyes Gómez, MD, M.Á. Correa, MD, M.G. Rosemffet, MD, V.C. Abarza, MD, M. Perandones, MD, G. Citera, MD, Instituto de Rehabilitación Psicofísica, Rheumatology Section., Abarza VC; O.L. Cerda, MD, E.E. Schneeberger, MD, M.A. Alfaro, MD, B.M. Roldán, MD, A.B. Gómez Vara, MD, P. Giorgis, MD, R.A. Ezquer, MD, M.G. Crespo Rocha, MD, C.R. Reyes Gómez, MD, M.Á. Correa, MD, M.G. Rosemffet, MD, V.C. Abarza, MD, M. Perandones, MD, G. Citera, MD, Instituto de Rehabilitación Psicofísica, Rheumatology Section., Pellet SC; M. Landi, MD, C. Calle Montoro, MD, S. Catalan Pellet, MD, C. Reimundes, MD, P. Maid, MD, Austral University Hospital, Rheumatology Department., Perandones M; O.L. Cerda, MD, E.E. Schneeberger, MD, M.A. Alfaro, MD, B.M. Roldán, MD, A.B. Gómez Vara, MD, P. Giorgis, MD, R.A. Ezquer, MD, M.G. Crespo Rocha, MD, C.R. Reyes Gómez, MD, M.Á. Correa, MD, M.G. Rosemffet, MD, V.C. Abarza, MD, M. Perandones, MD, G. Citera, MD, Instituto de Rehabilitación Psicofísica, Rheumatology Section., Reimundes C; M. Landi, MD, C. Calle Montoro, MD, S. Catalan Pellet, MD, C. Reimundes, MD, P. Maid, MD, Austral University Hospital, Rheumatology Department., Longueira Y; L. Cruces, BCh, Y. Longueira, MSc, G. Turk, PhD, M.F. Quiroga, PhD, N. Laufer, MD, PhD, Universidad de Buenos Aires, Consejo Nacional de Investigaciones Científicas y Técnicas, Instituto de Investigaciones Biomédicas en Retrovirus y Sida (INBIRS), Facultad de Medicina, Ciudad Autónoma de Buenos Aires., Turk G; L. Cruces, BCh, Y. Longueira, MSc, G. Turk, PhD, M.F. Quiroga, PhD, N. Laufer, MD, PhD, Universidad de Buenos Aires, Consejo Nacional de Investigaciones Científicas y Técnicas, Instituto de Investigaciones Biomédicas en Retrovirus y Sida (INBIRS), Facultad de Medicina, Ciudad Autónoma de Buenos Aires., Quiroga MF; L. Cruces, BCh, Y. Longueira, MSc, G. Turk, PhD, M.F. Quiroga, PhD, N. Laufer, MD, PhD, Universidad de Buenos Aires, Consejo Nacional de Investigaciones Científicas y Técnicas, Instituto de Investigaciones Biomédicas en Retrovirus y Sida (INBIRS), Facultad de Medicina, Ciudad Autónoma de Buenos Aires., Laufer N; L. Cruces, BCh, Y. Longueira, MSc, G. Turk, PhD, M.F. Quiroga, PhD, N. Laufer, MD, PhD, Universidad de Buenos Aires, Consejo Nacional de Investigaciones Científicas y Técnicas, Instituto de Investigaciones Biomédicas en Retrovirus y Sida (INBIRS), Facultad de Medicina, Ciudad Autónoma de Buenos Aires., Quintana R; R. Quintana, MD, G.J. Pons-Estel, MD, PhD, Research Unit - Argentine Society of Rheumatology., de la Vega MC; M.C. de la Vega, MD, Argentine Society of Rheumatology., Kreplak N; N. Kreplak, MD, MPH, M. Pifano, MSc, Ministry of Health of the Province of Buenos Aires, Buenos Aires, Argentina., Pifano M; N. Kreplak, MD, MPH, M. Pifano, MSc, Ministry of Health of the Province of Buenos Aires, Buenos Aires, Argentina., Maid P; M. Landi, MD, C. Calle Montoro, MD, S. Catalan Pellet, MD, C. Reimundes, MD, P. Maid, MD, Austral University Hospital, Rheumatology Department., Pons-Estel GJ; R. Quintana, MD, G.J. Pons-Estel, MD, PhD, Research Unit - Argentine Society of Rheumatology., Citera G; O.L. Cerda, MD, E.E. Schneeberger, MD, M.A. Alfaro, MD, B.M. Roldán, MD, A.B. Gómez Vara, MD, P. Giorgis, MD, R.A. Ezquer, MD, M.G. Crespo Rocha, MD, C.R. Reyes Gómez, MD, M.Á. Correa, MD, M.G. Rosemffet, MD, V.C. Abarza, MD, M. Perandones, MD, G. Citera, MD, Instituto de Rehabilitación Psicofísica, Rheumatology Section. |
| المصدر: | The Journal of rheumatology [J Rheumatol] 2022 Dec; Vol. 49 (12), pp. 1385-1389. Date of Electronic Publication: 2022 Oct 01. |
| نوع المنشور: | Journal Article; Research Support, Non-U.S. Gov't |
| اللغة: | English |
| بيانات الدورية: | Publisher: Journal Of Rheumatology Publishing Co Country of Publication: Canada NLM ID: 7501984 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 0315-162X (Print) Linking ISSN: 0315162X NLM ISO Abbreviation: J Rheumatol Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: Toronto : Journal Of Rheumatology Publishing Co Original Publication: Toronto. |
| مواضيع طبية MeSH: | COVID-19*/prevention & control , Vaccines* , Arthritis, Rheumatoid*/drug therapy, Humans ; COVID-19 Vaccines ; ChAdOx1 nCoV-19 ; BNT162 Vaccine ; SARS-CoV-2 ; Abatacept ; Immunoglobulin G ; Vaccination ; Rituximab ; Antibodies, Viral ; Immunity |
| مستخلص: | Objective: The aim of this study was to assess the immune response after a third dose of SARS-CoV-2 vaccine in patients with rheumatoid arthritis (RA) with undetectable antibody titers after the primary regimen of 2 doses. Methods: Patients with RA with no seroconversion after 2 doses of SARS-CoV-2 vaccine and who received a third dose of either an mRNA or vector-based vaccine were included. Anti-SARS-CoV-2 IgG antibodies, neutralizing activity, and T cell responses were assessed after the third dose. Results: A total of 21 nonresponder patients were included. At the time of vaccination, 29% were receiving glucocorticoids and 85% biologic disease-modifying antirheumatic drugs (including 6 taking abatacept [ABA] and 4 taking rituximab [RTX]). The majority (95%) received the BNT162b2 vaccine and only one of them received the ChAdOx1 nCoV-19 vaccine. After the third dose, 91% of the patients presented detectable anti-SARS-CoV-2 IgG and 76% showed neutralizing activity. Compared to other treatments, ABA and RTX were associated with the absence of neutralizing activity in 4 out of 5 (80%) patients and lower titers of neutralizing antibodies (median 3, IQR 0-20 vs 8, IQR 4-128; P = 0.20). Specific T cell response was detected in 41% of all patients after the second dose, increasing to 71% after the third dose. The use of ABA was associated with a lower frequency of T cell response (33% vs 87%, P = 0.03). Conclusion: In this RA cohort, 91% of patients who failed to seroconvert after 2 doses of SARS-CoV-2 vaccine presented detectable anti-SARS-CoV-2 IgG after a third dose. The use of ABA was associated with a lower frequency of specific T cell response. (Copyright © 2022 by the Journal of Rheumatology.) |
| التعليقات: | Comment in: J Rheumatol. 2022 Dec;49(12):1305-1306. (PMID: 36243410) |
| فهرسة مساهمة: | Keywords: Argentina; COVID-19; SARS-CoV-2; rheumatoid arthritis; vaccines |
| المشرفين على المادة: | 0 (COVID-19 Vaccines) B5S3K2V0G8 (ChAdOx1 nCoV-19) 0 (BNT162 Vaccine) 0 (Vaccines) 7D0YB67S97 (Abatacept) 0 (Immunoglobulin G) 4F4X42SYQ6 (Rituximab) 0 (Antibodies, Viral) |
| تواريخ الأحداث: | Date Created: 20221001 Date Completed: 20221205 Latest Revision: 20230105 |
| رمز التحديث: | 20240829 |
| DOI: | 10.3899/jrheum.220469 |
| PMID: | 36182107 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 0315-162X |
|---|---|
| DOI: | 10.3899/jrheum.220469 |